免疫组化改善小细胞肺癌诊断及其鉴别诊断:一组高难度病例的国际可重复性研究
19名肺病理学家对79例以神经内分泌肿瘤为主的肺部肿瘤数字图像进行判读,分别仅凭形态学、形态学联合所需免疫组化结果、全部免疫组化结果三个层级作出诊断。仅凭苏木精-伊红染色时一致性为中等,审慎使用免疫组化后多数病例一致性提高至良好,尤其在小细胞肺癌诊断中。
要点
- 仅凭形态学诊断时19名病理学家对79例的一致性为64.7%,联合所需免疫组化结果升至73.2%,全部免疫组化结果升至77.5%。
- 使用免疫组化后,四类肿瘤(小细胞肺癌、大细胞神经内分泌癌、类癌、其他)的κ值在切除标本由0.43升至0.60,活检标本由0.43升至0.64。
- 作者提供了小细胞肺癌鉴别诊断中免疫组化应用的方法。
核心结论
- 仅凭苏木精-伊红染色对具有神经内分泌形态的肿瘤进行诊断时,病理学家之间一致性为中等,但审慎使用免疫组化后多数病例一致性提高至良好,尤其在小细胞肺癌诊断中。
研究设计与样本
- 国际可重复性研究,19名肺病理学家判读79例以神经内分泌肿瘤为主的肺部肿瘤交互式数字图像,包括切除与活检标本。
- 诊断分三个层级:仅依据形态学特征(第1层级)、形态学特征联合 requested 免疫组化染色结果(第2层级)、全部可用免疫组化染色结果(第3层级)。
主要发现
- 19名病理学家判读全部79例时,第1层级一致率为64.7%,第2层级升至73.2%,第3层级升至77.5%。
- 使用免疫组化后,四类肿瘤(小细胞肺癌、大细胞神经内分泌癌、类癌、其他)的κ值在切除标本由0.43升至0.60,在活检标本由0.43升至0.64。
- 仅凭苏木精-伊红染色对具有神经内分泌形态的肿瘤诊断一致性为中等,审慎使用免疫组化后多数病例一致性提高至良好。
关键数值与推荐
- 第1层级一致率64.7%,第2层级73.2%,第3层级77.5%(19名病理学家判读全部79例)。
- 四类肿瘤κ值:切除标本由0.43升至0.60,活检标本由0.43升至0.64(使用免疫组化后)。
临床怎么用
- 作者提供了小细胞肺癌鉴别诊断中免疫组化应用的方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The current WHO classification of lung cancer states that a diagnosis of SCLC can be reliably made on routine histological and cytological grounds but immunohistochemistry (IHC) may be required, particularly (1) in cases in which histologic features are equivocal and (2) in cases in which the pathologist wants to increase confidence in diagnosis. However, reproducibility studies based on hematoxylin and eosin-stained slides alone for SCLC versus large cell neuroendocrine carcinoma (LCNEC) have shown pairwise κ scores ranging from 0.35 to 0.81. This study examines whether judicious use of IHC improves diagnostic reproducibility for SCLC. METHODS: Nineteen lung pathologists studied interactive digital images of 79 tumors, predominantly neuroendocrine lung tumors. Images of resection and biopsy specimens were used to make diagnoses solely on the basis of morphologic features (level 1), morphologic features along with requested IHC staining results (level 2), and all available IHC staining results (level 3). RESULTS: For the 19 pathologists reading all 79 cases, the rate of agreement for level 1 was 64.7%, and it increased to 73.2% and 77.5% in levels 2 and 3, respectively. With IHC, κ scores for four tumor categories (SCLC, LCNEC, carcinoid tumors, and other) increased in resection samples from 0.43 to 0.60 and in biopsy specimens from 0.43 to 0.64. CONCLUSIONS: Diagnosis using hematoxylin and eosin staining alone showeds moderate agreement among pathologists in tumors with neuroendocrine morphology, but agreement improved to good in most cases with the judicious use of IHC, especially in the diagnosis of SCLC. An approach for IHC in the differential diagnosis of SCLC is provided.
引用
- Thunnissen E, Borczuk AC, Flieder DB, et al. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. J Thorac Oncol. 2016. PMID: 27998793. doi:10.1016/j.jtho.2016.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。